Expression of concern regarding paper by Park et al, published on 25 June 2015: “Epidemiological investigation of MERS-CoV spread in a single hospital in South Korea, May to June 2015”, Euro Surveill. 2015;20(25):pii=21169. It has been brought to our attention that some of the authors may not have been informed about the content of the above paper. There is a lack of clarity regarding rights to use the data. The editorial team are investigating what action needs to be taken.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

Read our articles on Zika virus infection

Read our articles on mcr-1-mediated colistin resistance

In this issue

Home Eurosurveillance Edition  2008: Volume 13/ Issue 15 Article 4
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 13, Issue 15, 10 April 2008
Rapid communications
Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales
  1. Sexually Transmitted Bacteria Reference Laboratory, Centre for Infections, Health Protection Agency, London, the United Kingdom

Citation style for this article: Chisholm SA, Ison C. Emergence of high-level azithromycin resistance in Neisseria gonorrhoeae in England and Wales. Euro Surveill. 2008;13(15):pii=18832. Available online:
Date of submission: 10 April 2008

The Gonococcal Resistance to Antimicrobials Surveillance Programme (GRASP) in England and Wales has monitored azithromycin resistance since 2001. In 2007, high-level azithromycin resistance (MICs >256 mg/L) was identified for the first time in six isolates, all of which were the same sequence type (ST 649).

High-level azithromycin resistance has also been reported in Scotland, but it is not known if this has wider geographical dissemination. It has been recommended that gonococcal resistance to azithromycin should be monitored in regions or countries where this drug is used to treat Chlamydia trachomatis infection. Furthermore, specific anti-gonococcal therapy should always be used to treat gonorrhoea. Azithromycin is not a recommended treatment for gonorrhoea in the United Kingdom [1]. Further information on this emerging resistance can be found at and


  1. Clinical effectiveness group, British Association for Sexual Health and HIV.
    National Guideline on the Diagnosis and Treatment of Gonorrhoea in Adults 2005. Available from:

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN 1560-7917] - ©2007-2016. All rights reserved.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.